Top

Published in:

Open Access 10-06-2022 | Neuroblastoma | COMMENTARY

Targeting lipid metabolism in cancer: neuroblastoma

Authors: Massimiliano Agostini, Gerry Melino, Bola Habeb, Jorgelina M. Calandria, Nicolas G. Bazan

Published in: Cancer and Metastasis Reviews | Issue 2/2022

Excerpt

Neuroblastoma (NB) is the most common extracranial tumor among children with an average age of 17 months. NB is a tumor of the autonomic nervous system originating from embryonic neural crest cells [1] in which the pathogenesis of this malignancy is characterized by a block of differentiation [2, 3]. Many factors converge in this heterogeneous disease, including age, disease stage, and genetic and molecular features that, in turn, influence whether NB will spontaneously regress or metastasize and become resistant to therapy [4, 5]. Among the genetic alterations described in NB, MYCN amplification is the most common genetic dysfunction and is also associated with poor outcome. Moreover, mutations affecting both the α-thalassemia/mental retardation syndrome X-linked (ATRX) gene [6] or anaplastic lymphoma receptor tyrosine kinase (ALK) [7] are also common in NB. …

Maris, J.M., Hogarty, M.D., Bagatell, R., & Cohn, S.L. (2007). Neuroblastoma. Lancet (London, England), 369(9579), 2106–2120. https://doi.org/10.1016/S0140-6736(07)60983-0CrossRef

Thiele, C.J. (1991). Biology of pediatric peripheral neuroectodermal tumors. Cancer metastasis reviews, 10(4), 311–319. https://doi.org/10.1007/BF00554793CrossRefPubMed

Pieraccioli, M., Nicolai, S., Pitolli, C., Agostini, M., Antonov, A., Malewicz, M., & Melino, G. (2018). ZNF281 inhibits neuronal differentiation and is a prognostic marker for neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 115(28), 7356–7361. https://doi.org/10.1073/pnas.1801435115CrossRefPubMedPubMedCentral

Amelio, I., Bertolo, R., Bove, P., Candi, E., Chiocchi, M., Cipriani, C., & Melino, G. (2020). Cancer predictive studies. Biology direct, 15(1), 18. https://doi.org/10.1186/s13062-020-00274-3CrossRefPubMed

Nicolai, S., Pieraccioli, M., Peschiaroli, A., Melino, G., & Raschellà, G. (2015). Neuroblastoma: Oncogenic mechanisms and therapeutic exploitation of necroptosis. Cell death & disease, 6, e2010. https://doi.org/10.1038/cddis.2015.354CrossRef

Molenaar, J. J., Koster, J., Zwijnenburg, D. A., van Sluis, P., Valentijn, L. J., van der Ploeg, I., & Versteeg, R. (2012). Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature, 483(7391), 589–593. https://doi.org/10.1038/nature10910CrossRefPubMed

Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., & Maris, J. M. (2008). Identification of ALK as a major familial neuroblastoma predisposition gene. Nature, 455(7215), 930–935. https://doi.org/10.1038/nature07261CrossRefPubMedPubMedCentral

Cohn, S. L., Pearson, A. D. J., London, W. B., Monclair, T., Ambros, P. F., Brodeur, G. M., Task, I. N. R. G., & Force. (2009). The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. Journal of clinical oncology: Official journal of the American Society of Clinical Oncology, 27(2), 289–297. https://doi.org/10.1200/JCO.2008.16.6785CrossRef

Ragupathi, G., Livingston, P. O., Hood, C., Gathuru, J., Krown, S. E., Chapman, P. B., & Hwu, W.-J. (2003). Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clinical cancer research: An official journal of the American Association for Cancer Research, 9(14), 5214–5220.

10.

Billon, N., Terrinoni, A., Jolicoeur, C., McCarthy, A., Richardson, W. D., Melino, G., & Raff, M. (2004). Roles for p53 and p73 during oligodendrocyte development. Development (Cambridge, England), 131(6), 1211–1220. https://doi.org/10.1242/dev.01035CrossRef

11.

de Laurenzi, V., & Melino, G. (2000). Evolution of functions within the p53/p63/p73 family. Annals of the New York Academy of Sciences, 926, 90–100. https://doi.org/10.1111/j.1749-6632.2000.tb05602.xCrossRefPubMed

12.

Bellomaria, A., Barbato, G., Melino, G., Paci, M., & Melino, S. (2010). Recognition of p63 by the E3 ligase ITCH: Effect of an ectodermal dysplasia mutant. Cell cycle (Georgetown, Tex.), 9(18), 3730–9.

13.

Candi, E., Terrinoni, A., Rufini, A., Chikh, A., Lena, A. M., Suzuki, Y., & Melino, G. (2006). p63 is upstream of IKK alpha in epidermal development. Journal of cell science, 119(Pt 22), 4617–4622. https://doi.org/10.1242/jcs.03265CrossRefPubMed

14.

Candi, E., Cipollone, R., di Val, R., Cervo, P., Gonfloni, S., Melino, G., & Knight, R. (2008). p63 in epithelial development. Cellular and molecular life sciences: CMLS, 65(20), 3126–3133. https://doi.org/10.1007/s00018-008-8119-xCrossRefPubMed

15.

Candi, E., Agostini, M., Melino, G., & Bernassola, F. (2014). How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: Regulators and effectors. Human mutation, 35(6), 702–714. https://doi.org/10.1002/humu.22523CrossRefPubMed

16.

Agostini, M., Tucci, P., Killick, R., Candi, E., Sayan, B. S., di Val, R., Cervo, P., & Melino, G. (2011). Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proceedings of the National Academy of Sciences of the United States of America, 108(52), 21093–21098. https://doi.org/10.1073/pnas.1112061109CrossRefPubMedPubMedCentral

17.

Velletri, T., Romeo, F., Tucci, P., Peschiaroli, A., Annicchiarico-Petruzzelli, M., Niklison-Chirou, M. V., Agostini, M. (2013). GLS2 is transcriptionally regulated by p73 and contributes to neuronal differentiation. Cell cycle (Georgetown, Tex.), 12(22), 3564–73. https://doi.org/10.4161/cc.26771

18.

Tomasini, R., Tsuchihara, K., Tsuda, C., Lau, S. K., Wilhelm, M., Rufini, A., & Mak, T. W. (2009). TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proceedings of the National Academy of Sciences of the United States of America, 106(3), 797–802. https://doi.org/10.1073/pnas.0812096106CrossRefPubMedPubMedCentral

19.

Amelio, I., & Melino, G. (2015). The p53 family and the hypoxia-inducible factors (HIFs): Determinants of cancer progression. Trends in biochemical sciences, 40(8), 425–434. https://doi.org/10.1016/j.tibs.2015.04.007CrossRefPubMed

20.

Nepravishta, R., Sabelli, R., Iorio, E., Micheli, L., Paci, M., & Melino, S. (2012). Oxidative species and S-glutathionyl conjugates in the apoptosis induction by allyl thiosulfate. The FEBS journal, 279(1), 154–167. https://doi.org/10.1111/j.1742-4658.2011.08407.xCrossRefPubMed

21.

Mauretti, A., Neri, A., Kossover, O., Seliktar, D., di Nardo, P., & Melino, S. (2016). Design of a novel composite H2 S-releasing hydrogel for cardiac tissue repair. Macromolecular bioscience, 16(6), 847–858. https://doi.org/10.1002/mabi.201500430CrossRefPubMed

22.

Hattori, T., Takahashi, Y., Chen, L., Tang, Z., Wills, C. A., Liang, X., & Wang, H.-G. (2021). Targeting the ESCRT-III component CHMP2A for noncanonical caspase-8 activation on autophagosomal membranes. Cell death and differentiation, 28(2), 657–670. https://doi.org/10.1038/s41418-020-00610-0CrossRefPubMed

23.

Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984). Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (New York, N.Y.), 224(4653), 1121–4. https://doi.org/10.1126/science.6719137

24.

Dang, C., & v, Reddy, E. P., Shokat, K. M., & Soucek, L. (2017). Drugging the “undruggable” cancer targets. Nature reviews. Cancer, 17(8), 502–508. https://doi.org/10.1038/nrc.2017.36CrossRefPubMedPubMedCentral

25.

Gouw, A. M., Margulis, K., Liu, N. S., Raman, S. J., Mancuso, A., Toal, G. G., & Felsher, D. W. (2019). The MYC oncogene cooperates with sterol-regulated element-binding protein to regulate lipogenesis essential for neoplastic growth. Cell metabolism, 30(3), 556-572.e5. https://doi.org/10.1016/j.cmet.2019.07.012CrossRefPubMedPubMedCentral

26.

DeBerardinis, R. J., & Chandel, N. S. (2016). Fundamentals of cancer metabolism. Science advances, 2(5), e1600200. https://doi.org/10.1126/sciadv.1600200CrossRefPubMed

27.

Lindner, A. U., Salvucci, M., McDonough, E., Cho, S., Stachtea, X., O’Connell, E. P., & Prehn, J. H. M. (2022). An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution. Cell death and differentiation, 29(4), 806–817. https://doi.org/10.1038/s41418-021-00895-9CrossRefPubMed

28.

Rosa, N., Ivanova, H., Wagner, L. E., Kale, J., la Rovere, R., Welkenhuyzen, K., & Bultynck, G. (2022). Bcl-xL acts as an inhibitor of IP3R channels, thereby antagonizing Ca2+-driven apoptosis. Cell death and differentiation, 29(4), 788–805. https://doi.org/10.1038/s41418-021-00894-wCrossRefPubMed

29.

Humpton, T. J., Hall, H., Kiourtis, C., Nixon, C., Clark, W., Hedley, A., & Vousden, K. H. (2022). p53-mediated redox control promotes liver regeneration and maintains liver function in response to CCl4. Cell death and differentiation, 29(3), 514–526. https://doi.org/10.1038/s41418-021-00871-3CrossRefPubMed

30.

Fiorillo, M., Scatena, C., Naccarato, A. G., Sotgia, F., & Lisanti, M. P. (2021). Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase. Cell death and differentiation, 28(9), 2797–2817. https://doi.org/10.1038/s41418-021-00788-xCrossRefPubMedPubMedCentral

31.

Shulkin, B. L., Mitchell, D. S., Ungar, D. R., Prakash, D., Dole, M. G., Castle, V. P., & Hutchinson, R. J. (1995). Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies. Radiology, 194(2), 495–500. https://doi.org/10.1148/radiology.194.2.7824731CrossRefPubMed

32.

Levy, A. G., Zage, P. E., Akers, L. J., Ghisoli, M. L., Chen, Z., Fang, W., & Zweidler-McKay, P. A. (2012). The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma. Investigational new drugs, 30(1), 191–199. https://doi.org/10.1007/s10637-010-9551-yCrossRefPubMed

33.

White, P. S., Thompson, P. M., Seifried, B. A., Sulman, E. P., Jensen, S. J., Guo, C., & Brodeur, G. M. (2001). Detailed molecular analysis of 1p36 in neuroblastoma. Medical and pediatric oncology, 36(1), 37–41. https://doi.org/10.1002/1096-911X(20010101)36:1%3c37::AID-MPO1010%3e3.0.CO;2-LCrossRefPubMed

34.

King, A., Selak, M. A., & Gottlieb, E. (2006). Succinate dehydrogenase and fumarate hydratase: Linking mitochondrial dysfunction and cancer. Oncogene, 25(34), 4675–4682. https://doi.org/10.1038/sj.onc.1209594CrossRefPubMed

35.

Feichtinger, R. G., Zimmermann, F., Mayr, J. A., Neureiter, D., Hauser-Kronberger, C., Schilling, F. H., & Kofler, B. (2010). Low aerobic mitochondrial energy metabolism in poorly- or undifferentiated neuroblastoma. BMC Cancer, 10, 149. https://doi.org/10.1186/1471-2407-10-149CrossRefPubMedPubMedCentral

36.

Astuti, D., Morris, M., Krona, C., Abel, F., Gentle, D., Martinsson, T., & Maher, E. R. (2004). Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma. British journal of cancer, 91(10), 1835–1841. https://doi.org/10.1038/sj.bjc.6602202CrossRefPubMedPubMedCentral

37.

Bown, N., Cotterill, S., Lastowska, M., O’Neill, S., Pearson, A. D., Plantaz, D., & van Roy, N. (1999). Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. The New England journal of medicine, 340(25), 1954–1961. https://doi.org/10.1056/NEJM199906243402504CrossRefPubMed

38.

Islam, A., Kageyama, H., Takada, N., Kawamoto, T., Takayasu, H., Isogai, E., & Nakagawara, A. (2000). High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene, 19(5), 617–623. https://doi.org/10.1038/sj.onc.1203358CrossRefPubMed

39.

Hagenbuchner, J., Kuznetsov, A., & v, Obexer, P., & Ausserlechner, M. J. (2013). BIRC5/survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery. Oncogene, 32(40), 4748–4757. https://doi.org/10.1038/onc.2012.500CrossRefPubMed

40.

Carter, D. R., Sutton, S. K., Pajic, M., Murray, J., Sekyere, E. O., Fletcher, J., & Marshall, G. M. (2016). Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. Molecular oncology, 10(6), 866–878. https://doi.org/10.1016/j.molonc.2016.02.004CrossRefPubMedPubMedCentral

41.

Ren, P., Yue, M., Xiao, D., Xiu, R., Gan, L., Liu, H., & Qing, G. (2015). ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation. The Journal of pathology, 235(1), 90–100. https://doi.org/10.1002/path.4429CrossRefPubMed

42.

Carroll, P. A., Diolaiti, D., McFerrin, L., Gu, H., Djukovic, D., Du, J., & Eisenman, R. N. (2015). Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesis. Cancer Cell, 27(2), 271–285. https://doi.org/10.1016/j.ccell.2014.11.024CrossRefPubMedPubMedCentral

43.

Casinelli, G., LaRosa, J., Sharma, M., Cherok, E., Banerjee, S., Branca, M., & Graves, J. A. (2016). N-Myc overexpression increases cisplatin resistance in neuroblastoma via deregulation of mitochondrial dynamics. Cell death discovery, 2, 16082. https://doi.org/10.1038/cddiscovery.2016.82CrossRefPubMedPubMedCentral

44.

Zirath, H., Frenzel, A., Oliynyk, G., Segerström, L., Westermark, U. K., Larsson, K., & Henriksson, M. A. (2013). MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 110(25), 10258–10263. https://doi.org/10.1073/pnas.1222404110CrossRefPubMedPubMedCentral

45.

Oliynyk, G., Ruiz-Pérez, M. V., Sainero-Alcolado, L., Dzieran, J., Zirath, H., Gallart-Ayala, H., … Arsenian-Henriksson, M. (2019). MYCN-enhanced oxidative and glycolytic metabolism reveals vulnerabilities for targeting neuroblastoma. iScience, 21, 188–204. https://doi.org/10.1016/j.isci.2019.10.020

46.

Kihara, A. (2012). Very long-chain fatty acids: Elongation, physiology and related disorders. Journal of biochemistry, 152(5), 387–395. https://doi.org/10.1093/jb/mvs105CrossRefPubMed

47.

Bhattacharjee, S., Jun, B., Belayev, L., Heap, J., Kautzmann, M.-A., Obenaus, A., & Bazan, N. G. (2017). Elovanoids are a novel class of homeostatic lipid mediators that protect neural cell integrity upon injury. Science advances, 3(9), e1700735. https://doi.org/10.1126/sciadv.1700735CrossRefPubMedPubMedCentral

48.

Jun, B., Mukherjee, P. K., Asatryan, A., Kautzmann, M.-A., Heap, J., Gordon, W. C., & Bazan, N. G. (2017). Elovanoids are novel cell-specific lipid mediators necessary for neuroprotective signaling for photoreceptor cell integrity. Scientific reports, 7(1), 5279. https://doi.org/10.1038/s41598-017-05433-7CrossRefPubMedPubMedCentral

49.

Agbaga, M.-P., Brush, R. S., Mandal, M. N. A., Henry, K., Elliott, M. H., & Anderson, R. E. (2008). Role of Stargardt-3 macular dystrophy protein (ELOVL4) in the biosynthesis of very long chain fatty acids. Proceedings of the National Academy of Sciences of the United States of America, 105(35), 12843–12848. https://doi.org/10.1073/pnas.0802607105CrossRefPubMedPubMedCentral

50.

Rugolo, F., Bazan, N. G., Calandria, J., Jun, B., Raschellà, G., Melino, G., & Agostini, M. (2021). The expression of ELOVL4, repressed by MYCN, defines neuroblastoma patients with good outcome. Oncogene, 40(38), 5741–5751. https://doi.org/10.1038/s41388-021-01959-3CrossRefPubMed

51.

Chen, X., Kang, R., Kroemer, G., & Tang, D. (2021). Organelle-specific regulation of ferroptosis. Cell death and differentiation, 28(10), 2843–2856. https://doi.org/10.1038/s41418-021-00859-zCrossRefPubMed

52.

Yang, L., Hou, Y., Du, Y.-E., Li, Q., Zhou, F., Li, Y., & Liu, M. (2021). Mirtronic miR-4646-5p promotes gastric cancer metastasis by regulating ABHD16A and metabolite lysophosphatidylserines. Cell death and differentiation, 28(9), 2708–2727. https://doi.org/10.1038/s41418-021-00779-yCrossRefPubMedPubMedCentral

53.

Cui, W., Liu, D., Gu, W., & Chu, B. (2021). Peroxisome-driven ether-linked phospholipids biosynthesis is essential for ferroptosis. Cell death and differentiation, 28(8), 2536–2551. https://doi.org/10.1038/s41418-021-00769-0CrossRefPubMedPubMedCentral

54.

Snaebjornsson, M. T., Janaki-Raman, S., & Schulze, A. (2020). Greasing the wheels of the cancer machine: The role of lipid metabolism in cancer. Cell metabolism, 31(1), 62–76. https://doi.org/10.1016/j.cmet.2019.11.010CrossRefPubMed

55.

Göbel, A., Rauner, M., Hofbauer, L. C., & Rachner, T. D. (2020). Cholesterol and beyond - The role of the mevalonate pathway in cancer biology. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1873(2), 188351. https://doi.org/10.1016/j.bbcan.2020.188351

56.

Dickerman, B. A., García-Albéniz, X., Logan, R. W., Denaxas, S., & Hernán, M. A. (2019). Avoidable flaws in observational analyses: An application to statins and cancer. Nature medicine, 25(10), 1601–1606. https://doi.org/10.1038/s41591-019-0597-xCrossRefPubMedPubMedCentral

57.

McGregor, G. H., Campbell, A. D., Fey, S. K., Tumanov, S., Sumpton, D., Blanco, G. R., & Kamphorst, J. J. (2020). Targeting the metabolic response to statin-mediated oxidative stress produces a synergistic antitumor response. Cancer research, 80(2), 175–188. https://doi.org/10.1158/0008-5472.CAN-19-0644CrossRefPubMed

58.

Kant, S., Kesarwani, P., Prabhu, A., Graham, S. F., Buelow, K. L., Nakano, I., & Chinnaiyan, P. (2020). Enhanced fatty acid oxidation provides glioblastoma cells metabolic plasticity to accommodate to its dynamic nutrient microenvironment. Cell Death & Disease, 11(4), 253. https://doi.org/10.1038/s41419-020-2449-5CrossRef

59.

Conti, R., Mannucci, E., Pessotto, P., Tassoni, E., Carminati, P., Giannessi, F., & Arduini, A. (2011). Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis. Diabetes, 60(2), 644–651. https://doi.org/10.2337/db10-0346CrossRefPubMedPubMedCentral

60.

Makowski, K., Mir, J. F., Mera, P., Ariza, X., Asins, G., Hegardt, F. G., & Serra, D. (2017). (-)-UB006: A new fatty acid synthase inhibitor and cytotoxic agent without anorexic side effects. European journal of medicinal chemistry, 131, 207–221. https://doi.org/10.1016/j.ejmech.2017.03.012CrossRefPubMed

61.

Ruiz-Pérez, M. V., Sainero-Alcolado, L., Oliynyk, G., Matuschek, I., Balboni, N., Ubhayasekera, S. J. K. A., Arsenian-Henriksson, M. (2021). Inhibition of fatty acid synthesis induces differentiation and reduces tumor burden in childhood neuroblastoma. iScience, 24(2), 102128. https://doi.org/10.1016/j.isci.2021.102128

62.

Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Reynolds, C. P. (1999). Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. The New England journal of medicine, 341(16), 1165–73. https://doi.org/10.1056/NEJM199910143411601

63.

Peinemann, F., van Dalen, E. C., Enk, H., & Berthold, F. (2017). Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. The Cochrane database of systematic reviews, 8, CD010685. https://doi.org/10.1002/14651858.CD010685.pub3

64.

Cruz Flores, V. A., Menghani, H., Mukherjee, P. K., Marrero, L., Obenaus, A., Dang, Q., & Bazan, N. G. (2021). Combined therapy with avastin, a PAF receptor antagonist and a lipid mediator inhibited glioblastoma tumor growth. Frontiers in pharmacology, 12, 746470. https://doi.org/10.3389/fphar.2021.746470CrossRefPubMedPubMedCentral

Title: Targeting lipid metabolism in cancer: neuroblastoma
Authors: Massimiliano Agostini
Gerry Melino
Bola Habeb
Jorgelina M. Calandria
Nicolas G. Bazan
Publication date: 10-06-2022
Publisher: Springer US
Keywords: Neuroblastoma
Neuroblastoma
Published in: Cancer and Metastasis Reviews / Issue 2/2022
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-022-10040-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2022

Inflammatory bowel disease and carcinogenesis

Nanotechnology-aided advancement in the combating of cancer metastasis

The cure from within? a review of the microbiome and diet in melanoma

Biographies

Correction to: Connecting the human microbiome and pancreatic cancer

Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux

Keynote webinar | Spotlight on antibody–drug conjugates in cancer